Chemotherapy-Induced Anemia Market Size was valued at USD 2.4 Bn in 2023 and is predicted to reach USD 3.9 Bn by 2031 at a 6.5% CAGR during the forecast period for 2024-2031.
Chemotherapy induces anemia, a disorder characterized by decreased hemoglobin and red blood cells. This disease originates from the fast cell division that chemotherapy treatments frequently target. The market is being propelled primarily by the increasing recognition of the significance of anemia management in cancer therapy among both healthcare providers and patients. In addition, the availability of erythropoiesis-stimulating medicines and iron supplements has increased the need for therapies for chemotherapy-induced anemia, which in turn has boosted the growth of the chemotherapy-induced anemia market. Furthermore, market expansions are being propelled by the development of novel therapies, which in turn are being supported by rising investments in cancer research initiatives from governments, private organizations, and pharmaceutical companies, as well as by continuously improving research technologies. In addition, cancer patients’ quality of life has prompted oncologists to place a greater emphasis on effective chemotherapy-induced anemia.
However, the market's expansion is hindered by the stringent regulatory standards of chemotherapy-induced anemia, and creating therapy, researching, and developing strategies to target chemotherapy-induced anemia is a time-consuming and expensive endeavor. In addition, the market expansion is also hindered by the negative effects linked to chemotherapy-induced anemia therapies. Furthermore, factors driving market expansion include an uptick in cancer cases and fatalities globally and a surge in research and development efforts related to the creation of these medications. Chemotherapy-induced anemia is in high demand because cancer rates are increasing globally.
Competitive Landscape
Some of the Major Key Players in the Chemotherapy-Induced Anemia Market are
- Astellas Pharma Inc.
- Blausen Medical
- Dr. Reddy’s Laboratories Ltd.
- Elsevier Inc.
- F. Hoffmann-La Roche Ltd
- FibroGen, Inc.
- GlaxoSmithKline PLC
- Healio
- Johnson & Johnson
- Karger AG
- Novartis AG
- Pfizer Inc.
Market Segmentation:
The chemotherapy-induced anemia market is segmented based on a type of anemia, treatment type, drug type, and end-user. Based on anemia, the market is segmented into mild anemia, moderate anemia, severe anemia, and life-threatening anemia. By treatment type, the market is segmented into RBC transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation. By drug type, the market is segmented into epogen injection, procrit injection, androxy oral, Aranesp injection, epoetin alfa injection, and others. By end-user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.
Mild Anemia Segment is Accounted as a Major Contributor to the Chemotherapy-induced Anemia Market
The mild anemia market in chemotherapy-induced anemia is expected to hold a major global market share in 2023. This is because treating mild anemia, a common side effect among chemotherapy patients, is essential for curative cancer treatment and quality of life maintenance. Because of its ubiquity and the fact that it is in its early stages, mild anemia is more frequently diagnosed and treated than moderate cases.
Hospitals Segment to Witnessed Growth at a Rapid Rate
Hospitals are growing rapidly in the chemotherapy-induced anemia market because they treat a large number of cancer patients through chemotherapy, and many of these patients experience anemia as a side effect. Hospitals offer access to cutting-edge diagnostic techniques and specialized cancer care, making more precise diagnoses and individualized plans for managing anemia possible. The increasing focus on enhancing the well-being of cancer patients has prompted hospitals to place a premium on excellent chemotherapy-induced anemia management, which has contributed to their fast expansion in this sector.
In the Region, the North American Chemotherapy-induced Anemia Market Holds a Significant Revenue Share
The North American chemotherapy-induced anemia market is expected to register the highest market share in revenue in the near future. It can be attributed to the focus on establishing targeted treatments, elevated cancer rates, and a dramatic rise in public understanding of cancer prevention and treatment options. The rising need for therapies for chemotherapy-induced anemia is also fueling the expansion of this industry. In addition, Asia Pacific is anticipated to grow rapidly in the global chemotherapy-induced anemia market due to the region's vast population and the growing need for top-notch healthcare, the growing number of older adults, and the subsequent demand for better healthcare services and the need for cutting-edge medical technology.
Recent Developments:
- In May 2024, Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas, and Poseida Therapeutics, Inc., a publicly traded company, announced that they have formed a research collaboration and license agreement to create new convertible car programs. This will be achieved by combining the cutting-edge cell therapy platforms of both companies.
- In March 2024, Elsevier, a world leader in providing information solutions and products for science, technology, and medicine, is pleased to announce the launch of a new open-access journal, CMI Communications, in collaboration with ESCMID, the leading European society for clinical microbiology and infectious diseases.
Chemotherapy-Induced Anemia Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.4 Bn |
|
Revenue Forecast In 2031 |
USD 3.9 Bn |
|
Growth Rate CAGR |
CAGR of 6.5% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Anemia, By Treatment Type, By Drug Type, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Astellas Pharma Inc., Blausen Medical, Dr. Reddy’s Laboratories Ltd., Elsevier Inc., F. Hoffmann-La Roche Ltd, FibroGen, Inc., GlaxoSmithKline PLC, Healio, Johnson & Johnson, Karger AG, Novartis AG, and Pfizer Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
